This article is rated Start-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||
|
Individuals with a conflict of interest, particularly those representing the subject of the article, are strongly advised not to directly edit the article. See Wikipedia:Conflict of interest. You may request corrections or suggest content here on the Talk page for independent editors to review, or contact us if the issue is urgent. |
The following Wikipedia contributors may be personally or professionally connected to the subject of this article. Relevant policies and guidelines may include conflict of interest, autobiography, and neutral point of view. |
Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Souvenaid.
|
It would be nice to add the ingredients of the proprietary blend in the article. •Eicospentaenoic acid, 300 mg •Docosahexaenoic acid, 1200 mg •Phospholipids 106 mg •Choline, 400 mg •Uridine monophosphate, 625 mg •Vitamin E (alpha-tocopherol equivalents), 40 mg •Selenium, 60 µg •Vitamin B12, 3 µg •Vitamin B6, 1 mg •Folic acid, 400 µg Here is the reference. http://www.medscape.com/viewarticle/767960 I don't know where it would fit best in the article. If someone wants to add it, then go ahead.
This is the initial study on the supplement. There was no long-term examination and shorter term results were mixed.
http://www.j-alz.com/issues/31/scheltens_supplement.pdf — Preceding
unsigned comment added by
75.145.181.105 (
talk) 17:41, 15 January 2013 (UTC)
I pasted the note below that was left on my talk page in this diff and fixed the formatting. Jytdog ( talk) 14:00, 12 October 2017 (UTC)
This edit request by an editor with a conflict of interest was declined. |
Dear Jytdog, thank you for helping with Fortasyn Connect. Elifkos transmitted the problems before to you and you requested that no changes are done directly before contacting you by this talk page. I declare that I have a personal and academic link to Fortasyn Connect as I had been critically involved in the development my self and this would be an actual or conceived COI, which I herewith declare. I further declare that the wiki article I'm referring to was neither generated or modified by me before, nor did I or do I receive payment for my wiki contributions. My links are entirely academic. My motivation is that the current content is incorrect and both as academic scientist as well as someone who has been involved personally I want that the incorrect information is corrected. I do understand that wiki rules request that because of the COI changes should preferentially be reviewed and done by others. The paragraph on 'Development of concept' is incorrect in content, and without any suitable sources which would substantiate the currently presented (incorrect) content. Historical edits show that the content of this paragraph had never been correct and/or correctly sourced. I'm herewith asking you to exchange the unsubstantiated paragraph by the following substantiated paragraph. It does include primary sources, including primary peer reviewed scientific publications, peer reviewed scientific review source, presse releases and research web page links.
<redacted>
References 1. de Wilde MC, Farkas E, Gerrits M, Kiliaan AJ, Luiten PG: The effect of n-3 polyunsaturated fatty acid-rich diets on cognitive and cerebrovascular parameters in chronic cerebral hypoperfusion. Brain Res 2002, 947(2):166-173.
2. Farkas E, de Wilde MC, Kiliaan AJ, Meijer J, Keijser JN, Luiten PG: Dietary long chain PUFAs differentially affect hippocampal muscarinic 1 and serotonergic 1A receptors in experimental cerebral hypoperfusion. Brain Res 2002, 954(1):32-41.
3. de Bruin NMWJ, Kiliaan AJ, de Wilde MC, Broersen LM: Combined uridine and choline administration improves cognitive deficits in spontaneously hypertensive rats. Neurobiology of Learning and Memory 2003, 80(1):63-79.
4. https://idw-online.de/de/news647626
5. http://www.lipididiet.eu/index.php?id=16065
6. Hogyes E, Nykas C, Kiliaan A, Farkas T, Penke B and Luiten PGM: Neuroprotective effect of developmental DHA supplement against excitotoxic brain damage in infant rats. Neuroscience 2003, 119: 999–1012
7. de Wilde MC, Hogyes E, Kiliaan AJ, Farkas T, Luiten PG, Farkas E: Dietary fatty acids alter blood pressure, behavior and brain membrane composition of hypertensive rats. Brain Res 2003, 988(1-2):9-19.
8. Levi O, Lutjohann D, Devir A, von Bergmann K, Hartmann T, Michaelson DM: Regulation of hippocampal cholesterol metabolism by apoE and environmental stimulation. J Neurochem 2005, 95(4):987-997.
9. Grimm, M.O., H.S. Grimm, A.J. Patzold, E.G. Zinser, R. Halonen, M. Duering, J.A. Tschape, B. De Strooper, U. Muller, J. Shen, and T. Hartmann, (2005). Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat Cell Biol, 7: p. 1118-23 10. Oksman M, Iivonen H, Hogyes E, Amtul Z, Penke B, Leenders I, Broersen L, Lutjohann D, Hartmann T, Tanila H: Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis 2006, 23(3):563-572.
11. Hooijmans CR, Rutters F, Dederen PJ, Gambarota G, Veltien A, van Groen T, Broersen LM, Lutjohann D, Heerschap A, Tanila H and Kiliaan AJ: Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched typical western diet (TWD). Neurobiology of Disease 2007, 28(1):16-29.
12. Sakamoto T, Cansev M, Wurtman RJ: Oral supplementation with docosahexaenoic acid and uridine-5'-monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain Res 2007, 1182:50-59.
13. Teather LA, Wurtman RJ: Chronic administration of UMP ameliorates the impairment of hippocampal-dependent memory in impoverished rats. J Nutr 2006, 136(11):2834-2837.
14. Wurtman RJ, Ulus IH, Cansev M, Watkins CJ, Wang L, Marzloff G: Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally. Brain Res 2006, 1088(1):83-92.
Thank you for your help
WDMSID (
talk) 13:53, 12 October 2017 (UTC)
Thank you for your comments. Your comments are vague, you provide statements for which no evidence is given. Your statements are general in nature and do not identify which part/parts of the proposed changes you are referring to. I assume you as much as I want to improve the quality and accuracy of that page, let's work together to get it sorted out.
The requested is to now correct an unsourced paragraph, alternative action requested is to now delete the unsourced paragraph which may lead at any later point in time to correctly sourced content.
Thank you for commitment to Wikipedia WDMSID ( talk) 11:49, 13 October 2017 (UTC)
Dear Jytdog, thank you for your efforts on clarification and keeping the page to Wikipedia standards. Please find answers to your questions below. I am hoping this helpful and provided in the correct way?
The respective contribution is transparent from the scientific literature cited. The citations also show the contribution from the researchers not mentioned by name above, but nevertheless critically involved.
The list of scientific sources was a basis for the approval process by scientists and ethical commissions to proceed to further evaluation of Souvenaid in clinical trials. The scientific literature cited is from scientifically peer reviewed articles published in respectable scientific journals. The Vancouver Sun articles you recently sourced and linked to the article are very interesting, while they themselves don’t give any detail regarding the development, they do link to original reporting by the same journalist. There [18] one finds actual reporting about the contribution by the Wurtman Group, the identification of uridine monophosphate as a potentially important nutrient in this context (15-17). Uridine monophosphate was evaluated(3) and this nutrient was added to the 10 other nutrients already identified(1,2). The then 11 (and several other) nutrient combination was investigated(9-14) to see whether it may be suitable for clinical investigation. I suggest to replace or amend these sources by the sources presented above and to modify the text accordingly. Most of these references are scientific in nature, and for most no non-scientific secondary’s appear to exist. With the information and references provided a Wikipedia user interested in that preclinical development would be able to understand and trace back the science which led to Souvenaid. Please don’t hesitate to ask if I or anyone else could help to clarify remaining questions.
References
WDMSID ( talk) 12:07, 20 October 2017 (UTC)
Dear JYTDOG, I came across the discussion on this page, and as a scientist myself, in this instance it would seem to make sense to recognize the different scientific contributions to the invention as requested by WDMSID. The references clearly show a role of several research groups in the development of the concept, even receiving grant funding which I know is not easy to obtain. Thijsvdbroek ( talk) 13:15, 25 October 2017 (UTC)
Why so high DHA content and low EPA content? Is Souvenaid only effective in people who don't already take a lot of EPA/DHA supplements? ee1518 ( talk) 02:42, 3 December 2017 (UTC)
This article is rated Start-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||
|
Individuals with a conflict of interest, particularly those representing the subject of the article, are strongly advised not to directly edit the article. See Wikipedia:Conflict of interest. You may request corrections or suggest content here on the Talk page for independent editors to review, or contact us if the issue is urgent. |
The following Wikipedia contributors may be personally or professionally connected to the subject of this article. Relevant policies and guidelines may include conflict of interest, autobiography, and neutral point of view. |
Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Souvenaid.
|
It would be nice to add the ingredients of the proprietary blend in the article. •Eicospentaenoic acid, 300 mg •Docosahexaenoic acid, 1200 mg •Phospholipids 106 mg •Choline, 400 mg •Uridine monophosphate, 625 mg •Vitamin E (alpha-tocopherol equivalents), 40 mg •Selenium, 60 µg •Vitamin B12, 3 µg •Vitamin B6, 1 mg •Folic acid, 400 µg Here is the reference. http://www.medscape.com/viewarticle/767960 I don't know where it would fit best in the article. If someone wants to add it, then go ahead.
This is the initial study on the supplement. There was no long-term examination and shorter term results were mixed.
http://www.j-alz.com/issues/31/scheltens_supplement.pdf — Preceding
unsigned comment added by
75.145.181.105 (
talk) 17:41, 15 January 2013 (UTC)
I pasted the note below that was left on my talk page in this diff and fixed the formatting. Jytdog ( talk) 14:00, 12 October 2017 (UTC)
This edit request by an editor with a conflict of interest was declined. |
Dear Jytdog, thank you for helping with Fortasyn Connect. Elifkos transmitted the problems before to you and you requested that no changes are done directly before contacting you by this talk page. I declare that I have a personal and academic link to Fortasyn Connect as I had been critically involved in the development my self and this would be an actual or conceived COI, which I herewith declare. I further declare that the wiki article I'm referring to was neither generated or modified by me before, nor did I or do I receive payment for my wiki contributions. My links are entirely academic. My motivation is that the current content is incorrect and both as academic scientist as well as someone who has been involved personally I want that the incorrect information is corrected. I do understand that wiki rules request that because of the COI changes should preferentially be reviewed and done by others. The paragraph on 'Development of concept' is incorrect in content, and without any suitable sources which would substantiate the currently presented (incorrect) content. Historical edits show that the content of this paragraph had never been correct and/or correctly sourced. I'm herewith asking you to exchange the unsubstantiated paragraph by the following substantiated paragraph. It does include primary sources, including primary peer reviewed scientific publications, peer reviewed scientific review source, presse releases and research web page links.
<redacted>
References 1. de Wilde MC, Farkas E, Gerrits M, Kiliaan AJ, Luiten PG: The effect of n-3 polyunsaturated fatty acid-rich diets on cognitive and cerebrovascular parameters in chronic cerebral hypoperfusion. Brain Res 2002, 947(2):166-173.
2. Farkas E, de Wilde MC, Kiliaan AJ, Meijer J, Keijser JN, Luiten PG: Dietary long chain PUFAs differentially affect hippocampal muscarinic 1 and serotonergic 1A receptors in experimental cerebral hypoperfusion. Brain Res 2002, 954(1):32-41.
3. de Bruin NMWJ, Kiliaan AJ, de Wilde MC, Broersen LM: Combined uridine and choline administration improves cognitive deficits in spontaneously hypertensive rats. Neurobiology of Learning and Memory 2003, 80(1):63-79.
4. https://idw-online.de/de/news647626
5. http://www.lipididiet.eu/index.php?id=16065
6. Hogyes E, Nykas C, Kiliaan A, Farkas T, Penke B and Luiten PGM: Neuroprotective effect of developmental DHA supplement against excitotoxic brain damage in infant rats. Neuroscience 2003, 119: 999–1012
7. de Wilde MC, Hogyes E, Kiliaan AJ, Farkas T, Luiten PG, Farkas E: Dietary fatty acids alter blood pressure, behavior and brain membrane composition of hypertensive rats. Brain Res 2003, 988(1-2):9-19.
8. Levi O, Lutjohann D, Devir A, von Bergmann K, Hartmann T, Michaelson DM: Regulation of hippocampal cholesterol metabolism by apoE and environmental stimulation. J Neurochem 2005, 95(4):987-997.
9. Grimm, M.O., H.S. Grimm, A.J. Patzold, E.G. Zinser, R. Halonen, M. Duering, J.A. Tschape, B. De Strooper, U. Muller, J. Shen, and T. Hartmann, (2005). Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat Cell Biol, 7: p. 1118-23 10. Oksman M, Iivonen H, Hogyes E, Amtul Z, Penke B, Leenders I, Broersen L, Lutjohann D, Hartmann T, Tanila H: Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis 2006, 23(3):563-572.
11. Hooijmans CR, Rutters F, Dederen PJ, Gambarota G, Veltien A, van Groen T, Broersen LM, Lutjohann D, Heerschap A, Tanila H and Kiliaan AJ: Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched typical western diet (TWD). Neurobiology of Disease 2007, 28(1):16-29.
12. Sakamoto T, Cansev M, Wurtman RJ: Oral supplementation with docosahexaenoic acid and uridine-5'-monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain Res 2007, 1182:50-59.
13. Teather LA, Wurtman RJ: Chronic administration of UMP ameliorates the impairment of hippocampal-dependent memory in impoverished rats. J Nutr 2006, 136(11):2834-2837.
14. Wurtman RJ, Ulus IH, Cansev M, Watkins CJ, Wang L, Marzloff G: Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally. Brain Res 2006, 1088(1):83-92.
Thank you for your help
WDMSID (
talk) 13:53, 12 October 2017 (UTC)
Thank you for your comments. Your comments are vague, you provide statements for which no evidence is given. Your statements are general in nature and do not identify which part/parts of the proposed changes you are referring to. I assume you as much as I want to improve the quality and accuracy of that page, let's work together to get it sorted out.
The requested is to now correct an unsourced paragraph, alternative action requested is to now delete the unsourced paragraph which may lead at any later point in time to correctly sourced content.
Thank you for commitment to Wikipedia WDMSID ( talk) 11:49, 13 October 2017 (UTC)
Dear Jytdog, thank you for your efforts on clarification and keeping the page to Wikipedia standards. Please find answers to your questions below. I am hoping this helpful and provided in the correct way?
The respective contribution is transparent from the scientific literature cited. The citations also show the contribution from the researchers not mentioned by name above, but nevertheless critically involved.
The list of scientific sources was a basis for the approval process by scientists and ethical commissions to proceed to further evaluation of Souvenaid in clinical trials. The scientific literature cited is from scientifically peer reviewed articles published in respectable scientific journals. The Vancouver Sun articles you recently sourced and linked to the article are very interesting, while they themselves don’t give any detail regarding the development, they do link to original reporting by the same journalist. There [18] one finds actual reporting about the contribution by the Wurtman Group, the identification of uridine monophosphate as a potentially important nutrient in this context (15-17). Uridine monophosphate was evaluated(3) and this nutrient was added to the 10 other nutrients already identified(1,2). The then 11 (and several other) nutrient combination was investigated(9-14) to see whether it may be suitable for clinical investigation. I suggest to replace or amend these sources by the sources presented above and to modify the text accordingly. Most of these references are scientific in nature, and for most no non-scientific secondary’s appear to exist. With the information and references provided a Wikipedia user interested in that preclinical development would be able to understand and trace back the science which led to Souvenaid. Please don’t hesitate to ask if I or anyone else could help to clarify remaining questions.
References
WDMSID ( talk) 12:07, 20 October 2017 (UTC)
Dear JYTDOG, I came across the discussion on this page, and as a scientist myself, in this instance it would seem to make sense to recognize the different scientific contributions to the invention as requested by WDMSID. The references clearly show a role of several research groups in the development of the concept, even receiving grant funding which I know is not easy to obtain. Thijsvdbroek ( talk) 13:15, 25 October 2017 (UTC)
Why so high DHA content and low EPA content? Is Souvenaid only effective in people who don't already take a lot of EPA/DHA supplements? ee1518 ( talk) 02:42, 3 December 2017 (UTC)